Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Sells $89,380.94 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 21,383 shares of the stock in a transaction on Monday, December 29th. The stock was sold at an average price of $4.18, for a total transaction of $89,380.94. Following the transaction, the chief financial officer directly owned 761,550 shares in the company, valued at $3,183,279. The trade was a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ:RXRX opened at $4.09 on Friday. The stock has a market capitalization of $2.13 billion, a P/E ratio of -2.27 and a beta of 0.95. The business has a 50-day moving average of $4.62 and a two-hundred day moving average of $5.08. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business had revenue of $5.18 million for the quarter, compared to the consensus estimate of $19.36 million. During the same period last year, the business earned ($0.34) EPS. The firm’s revenue was down 80.1% compared to the same quarter last year. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. UBS Group set a $11.00 price target on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, September 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.50.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Recursion Pharmaceuticals by 183.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock valued at $33,901,000 after purchasing an additional 4,149,346 shares during the period. Vanguard Group Inc. boosted its stake in Recursion Pharmaceuticals by 10.3% during the third quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock worth $194,127,000 after buying an additional 3,708,975 shares in the last quarter. Norges Bank acquired a new stake in Recursion Pharmaceuticals during the second quarter worth $16,040,000. Bank Pictet & Cie Europe AG bought a new stake in Recursion Pharmaceuticals in the 3rd quarter valued at $7,954,000. Finally, Geode Capital Management LLC raised its stake in shares of Recursion Pharmaceuticals by 20.7% in the 2nd quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after buying an additional 1,332,428 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.